Two hundred and fifty biopsy specimens from the contralateral testis in patients with unilateral germinal testicular cancer were analysed by light microscopy for carcinoma-in-situ changes. Changes were found in 13 (5 2%) patients. One-third of patients with an atrophic contralateral testis (volume <12 ml) and one-fifth of patients with a history of cryptorchidism had changes in the remaining testis. In the present series 85% of cases with carcinoma-in-situ changes would have been diagnosed if the one-fifth of the patients having an atrophic testis or a history of cryptorchidism or both had been screened.
Introduction
Patients with germinal testicular cancer have an increased risk of also developing a cancer in the contralateral testis.1-3 The second cancer may arise several years later.3 A neoplasia may, however, be present as clinically undetectable carcinoma-insitu changes of the contralateral testis at the time of treatment of the first tumour.4 6 Consequently, we initiated screening for carcinoma-in-situ changes in the contralateral testis of patients with germinal testicular cancer in order to diagnose the condition at a preinvasive stage.
Patients and methods
During the period July 1972 to February 1982,250 biopsy specimens from the contralateral testis in patients with unilateral germinal testis cancer were analysed. During the first six years 13 biopsy specimens were received from one hospital whereas during the remaining years an increasing number of surgical departments participated in the study. During the last two years about 7500 of new patients with cancer of the testis in the eastern half of Denmark were screened. No selection of patients was performed according to medical history or clinical features. The age and diagnosis of the patients are given in table I. All patients were investigated and treated according to the 
contralateral testis. Lastly, it is not known whether carcinoma-in-situ cells always progress to invasive cancer, although actual spontaneous disappearance of these cells in the testis has never been demonstrated. '5 Reduced testicular volume was a striking clinical feature of the contralateral testes with carcinoma in situ, as it is in the testes with carcinoma in situ of infertile patients.5 Almost half the patients with carcinoma in situ had a history of unilateral or bilateral cryptorchidism. This is similar to the incidence of cryptorchidism in patients with bilateral germinal testicular cancer.2 3 Although the pathophysiological relationship between carcinoma in situ, cryptorchidism, and small testes has not been determined, the increased incidence of these two clinical features in the group of patients with carcinoma in situ of the contralateral testis may be used in the future to identify subpopulations In total group, 5-2",, (3) (4) (5) (6) (7) (8) (9) .
in situ. The remaining three patients have been followed for three to eight months with no clinical evidence of tumour formaition but they
have not yet had a second biopsy performed. Three biopsies were uninterpretable because of faulty preparation. In one of these patients a non-seminoma became clinically evident 30 months after irradiation and chemotherapy for a non-seminoma stage I tumour. None of the 234 patients without carcinoma-in-situ changes in the pretreatment biopsy specimen developed a tumour in the contralateral testis during the observation period.
Discussion
The incidence of carcinoma in situ in the contralateral testis was found to be twice as high as the presumed incidence of 1-5-2-8% of bilateral germinal testicular cancer.'-3 4 There may be several reasons for this. Firstly, the incidence of a second tumour arising in the contralateral testis is probably presently underestimated owing to a scarcity of prolonged and prospective investigations of unselected populations of patients with testicular cancer. Secondly, some testes with carcinoma-in-situ germ cells may not produce clinically detectable cancers before the of patients with testicular cancer who are at greater risk of carcinoma in situ in the remaining testis. In retrospect 11 out of 13 cases of carcinoma in situ in the present study would have been diagnosed if patients with a testis of 12 ml or less or cryptorchidism or both had been examined. This would have reduced the screened population to about one-fifth of its present size. Our study did not determine whether other factors such as infertility or type of tumour were of use in defining populations to be screened.
There is no agreement on the management of carcinoma in situ in the remaining testis in patients with testicular cancer, '6 mainly because the spontaneous course of the disease in these patients is unknown. The observation time of the present 13 patients with carcinoma in situ is still too short to elucidate this aspect, but at present two of the five patients who have been followed for more than three years have developed an invasive tumour.
In two of our patients chemotherapy may have modified the natural course of the carcinoma in situ, as follow-up biopsies failed to show changes. Continued observation will indicate whether this treatment can actually eradicate the premalignancy.
The degree of risk of not finding an existing carcinoma in situ at biopsy is unknown, but the changes are often found in most parts of the testis because they are multifocal and appear to spread along the affected tubules. Thus, the chance of detecting a carcinoma in situ by one biopsy has been found to be high even in cases where the actual volume of tubules with carcinoma in situ was less than 10% of the testicular volume.'7 To date none of the patients without carcinoma in situ in the biopsy specimen has developed a tumour, but a much longer follow-up time is needed.
We thank the oncological departments at the Finsen Institute and Herlev Hospital for their helpful co-operation, the participating surgical departments, and the institutes of pathology at the Finsen Institute and Herlev Hospital for providing histological material. We gratefully acknowledge the technical assistance of Mrs Anneliese Persson. The study was supported by grants from the Danish Cancer Society and the Danish Medical Research Council. Introduction A previous study in patients with homozygous sickle-cell disease aged over 401 indicated a strong positive correlation between haemoglobin concentration and creatinine clearance. Haemoglobin concentrations appeared to be adversely affected by fairly minor degrees of renal insufficiency, and we postulated that the bone marrow might be very sensitive to reduced erythropoietin concentrations. We investigated this possibility further by measuring serum concentrations of erythropoiesisstimulating factor, renal function, and haemoglobin concentrations in 31 adults with sickle-cell disease who were in a steady state (that is, free of acute complications of their disease) at the time of study.
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Patients and methods
Patients with sickle-cell disease were chosen from those attending the sickle-cell clinic of the University Hospital of the West Indies, Jamaica, on the basis of their willingness to take part in the study. Each was admitted electively to hospital when free of acute complications of their disease. The diagnosis of sickle-cell disease was based on a single major haemoglobin band in the position of haemoglobin S on cellulose acetate and agar-gel electrophoresis, compatible haemoglobin A2 concentrations, and family study when possible. No patient had received a transfusion within three months, and only two had been included in the earlier study. ' Creatinine clearance was determined from two consecutive 24-hour collections of urine and accompanying measurements of serum creatinine concentration, and the result was expressed as the mean of the two estimations, corrected for surface area derived from height and weight. Blood was drawn for measurement of serum urea concentration and standard haematological variables. Erythropoiesisstimulating factor was measured by a modification of the fetal mouse liver cell assay described by Wardle et a12 using sera stored without preservative at -70'C and thawed only once, just before the estimation. After overnight incubation of cell cultures in the presence of either test serum or pooled normal serum supplemented with sheep erythropoietin (stage III, Connaught Laboratories) activity of erythroid precursor cells was measured by the rate of incorporation of iron-59-labelled ferrous citrate into haem. Differences in uptake of 59Fe because of differences in the iron content of sera were prevented by adding an excess of human transferrin. The mean normal values for this laboratory in 11 male and 10 female American subjects were 12-8 U/I (range 4-5-19 8 U/I) and 17-2 U/I (range 10-8-27-0 U/1) respectively.
Student's t test and linear regression were used for statistical testing of results. As noted by others,3 concentrations of erythropoiesisstimulating factor had a skewed distribution, and logarithmic transformation was therefore performed before analysis.
Results
The study group consisted of 11 men and 20 women with a mean age of 37-1 years (range 15-66 years). Five were already known to have renal failure (creatinine clearance 4-23 ml/min/1-73 m2n) accompanied by appreciable anaemia (haemoglobin concentration 3-0-4-9 g/dl). Two of these (women aged 64 and 65 years) had been
